UAB Teva Baltics

UAB Teva Baltics is the Lithuanian subsidiary of Teva Pharmaceutical Industries Ltd., an Israeli-headquartered multinational pharmaceutical company specializing in generic and specialty medicines. In Lithuania, UAB Teva Baltics focuses on the commercialization, distribution, regulatory compliance, and pharmacovigilance of Teva’s portfolio for the local market. The company is part of Teva’s Baltic cluster covering Lithuania, Latvia, and Estonia.

Company Overview

Legal Name: UAB Teva Baltics
Country: Lithuania
Industry: Pharmaceuticals (generic and specialty medicines; OTC)
Founding/Presence in Lithuania: Teva established operations in the Baltic region in the early 2000s; the precise Lithuanian incorporation date for UAB Teva Baltics is not publicly listed on Teva’s local site and should be confirmed via official registries (see Sources).
Headquarters (Lithuania): Vilnius (specific registered office address not published on the public-facing Teva Lithuania site; see Legal Information).

Legal Information

Įmonės kodas (company code): Not publicly listed on Teva’s official Lithuanian channels. Consult Lithuania’s Juridinių asmenų registras (Companies Register) or business directories for the authoritative record.
PVM kodas (VAT code): Not publicly listed on Teva’s official Lithuanian channels. Verify via the Companies Register or VIES VAT system as applicable.
Official Website: https://www.teva.lt (local) and https://www.teva.com (global)
Email Address: A public, company-wide Lithuanian email is not listed on the local site. Teva typically directs inquiries via its website contact forms and country-specific medical information channels; exact Lithuanian email endpoints should be confirmed on the official site or via the State Medicines Control Agency (VVKT) contact guidance.
Registered Office Address (Lithuania): The full registered address for UAB Teva Baltics is not published on Teva’s public Lithuanian site. It can be obtained from Lithuania’s Juridinių asmenų registras (Registrų centras).
Phone Number (Lithuania): Not publicly listed on the Teva Lithuania site; use the official website contact form or consult the Companies Register/authorized directories for the latest phone number.

Business Operations

Main Products/Services:
- Prescription generic medicines across key therapeutic areas (e.g., CNS, cardiovascular, respiratory, oncology support, anti-infectives), depending on local registrations.
- Selected specialty medicines and biosimilars authorized in the EU and introduced based on Lithuanian market approvals.
- Over-the-counter (OTC) consumer health products carried by Teva in Europe, adapted to the Lithuanian portfolio and regulatory approvals.

Business Model:
- Market authorization, regulatory and pharmacovigilance oversight for Teva products in Lithuania.
- Wholesale distribution via established Lithuanian and Baltic wholesalers and logistics partners (GDP-compliant).
- Promotion and medical information for healthcare professionals within the national regulatory framework.
- Participation in hospital tenders and reimbursement processes; alignment with national health authorities and payers.

Market Position: Teva is among the leading generic medicines suppliers in Europe. In Lithuania, UAB Teva Baltics is generally positioned as a significant provider of generics and select specialty therapies. Precise market share figures specific to Lithuania are not publicly disclosed by the company.

History

Founding Story and Regional Build-out: Teva Pharmaceutical Industries expanded in Central and Eastern Europe during the early 2000s, notably through acquisitions such as Ivax Corporation (2006) and Barr Pharmaceuticals (2008), which strengthened its European footprint. Teva’s formalized presence in the Baltics emerged alongside these expansions and subsequent integration into Teva’s European commercial structure.

Key Milestones (Global Context Impacting Baltics):
- 2006: Acquisition of Ivax provided broader product portfolios and market access across Europe.
- 2008: Acquisition of Barr Pharmaceuticals further expanded Teva’s European generics base.
- 2016–2024: Ongoing portfolio optimization, compliance strengthening, and a strategic shift (“Pivot to Growth”) focusing on innovation, biosimilars, and key specialty launches in select markets; local Baltic activities align with EU approvals and national registrations.

Financial Information

Local Revenue: As a private limited company in Lithuania, UAB Teva Baltics does not publicly disclose standalone financial statements in Teva’s global investor communications. Detailed local financials, if available, can be obtained via Lithuanian registries for a fee.
Parent Company Financials: Teva Pharmaceutical Industries Ltd. is publicly listed; in recent years Teva reported annual revenues in the mid-teens USD billions (e.g., approximately USD 15–16 billion range). See Teva’s investor relations site for exact, latest figures.
Funding Rounds: N/A at the subsidiary level; UAB Teva Baltics is a corporate subsidiary, not a venture-funded entity.
Ownership Structure: UAB Teva Baltics is wholly owned (directly or indirectly) by Teva Pharmaceutical Industries Ltd., Israel.

Leadership and Management

Executives (Vadovai): Teva typically appoints a Baltics General Manager or Country Manager overseeing Lithuania, Latvia, and Estonia, alongside functional leads for regulatory affairs, market access, medical, pharmacovigilance, and commercial operations. However, the Teva Lithuania public-facing website does not list named executives.
Board Members: Specific board compositions for UAB Teva Baltics are maintained in the Lithuanian Companies Register. Names and roles are not published on Teva’s local site and should be verified in the official registry.

Office Locations

Primary Office (Lithuania): Vilnius. The exact registered office address and phone number are not listed on the Teva Lithuania website.
Additional Baltic Offices: Teva operates across Latvia and Estonia within the Baltic cluster. Specific office addresses and phone numbers for Latvia and Estonia should be confirmed via respective national registries or Teva’s regional contact channels.
Note: For authoritative addresses and phone numbers, consult the Companies Register (Registrų centras) and official directories (see Sources).

Market Position

Competitors in Lithuania: Other generic and branded pharmaceutical companies active in Lithuania include Sandoz (Novartis generics), STADA, Viatris (Mylan/Upjohn), KRKA, Zentiva, Accord Healthcare, and local/regionally active manufacturers and distributors. Competitive dynamics vary by therapeutic area, reimbursement status, and tender cycles.
Competitive Advantages: Teva’s broad and diversified portfolio, global manufacturing footprint, established quality systems (GMP/GDP), supply chain scale, and experienced regulatory and pharmacovigilance capabilities support consistent market presence. The company’s ability to introduce EU-authorized innovations and biosimilars further strengthens its offering.
Market Share: Precise Lithuanian market share figures are not published by UAB Teva Baltics; independent market research firms and national reimbursement reports provide granular insights.

Recent Developments

Global Strategy (“Pivot to Growth”): Teva announced a multi-year strategic focus on streamlining its generics base while accelerating specialty and biosimilar launches, and optimizing operational efficiency. Local Baltic activities reflect EU product authorizations and national registrations.
Regional Activities: Recent Lithuania-specific announcements are not listed on the public Teva Lithuania site. New product introductions and line extensions typically follow EU approvals and VVKT listings; consult VVKT resources for up-to-date market authorizations.

Contact Information

Official Website (Lithuania): https://www.teva.lt
Global Contact Portal: https://www.teva.com/contact-us/
Email: A single, public Lithuanian inbox is not listed on teva.lt; contact forms and medical information channels are used. For medicine safety or medical inquiries, Teva typically provides country-specific instructions via its site or national agency listings.
Registered Office Address (Lithuania): Not publicly listed on teva.lt; retrieve via Lithuania’s Companies Register (Registrų centras).
Phone: Not publicly listed on teva.lt; use the website contact portal or verify via official registries.

Sources and References

- Teva Lithuania website (company and product information, contact pathways): https://www.teva.lt
- Teva global corporate site: https://www.teva.com
- Teva Investor Relations (financials, strategy updates): https://ir.tevapharm.com
- Lithuania’s Juridinių asmenų registras (Companies Register, official company data): https://www.registrucentras.lt/jar/
- Rekvizitai.lt (Lithuanian business directory; consult for company codes and contacts): https://rekvizitai.vz.lt/
- State Medicines Control Agency (VVKT) for medicinal product authorizations and safety information in Lithuania: https://www.vvkt.lt

Notes on Data Availability

- The exact Lithuanian legal identifiers (įmonės kodas, PVM kodas), registered office address, named executives, and phone numbers for UAB Teva Baltics are maintained in official registries and may not be published on Teva’s public-facing Lithuanian site. For authoritative, up-to-date details, consult the Companies Register (Registrų centras) and recognized Lithuanian business directories.